Anti-viral developer Alios raises $8M more for $32M
Alios BioPharma, developer of anti-viral therapies, has tacked $8 million onto its first round of funding, bringing its total to $32 million. The new money came solely from SR One. Based in South San Francisco, the company plans to use the money to push its lead compound past phase-one trials.
Alios brought in the initial $24 million from Novartis Ventures, Novo AS and Roche Venture Fund.
Intradigm, a gene targeting co., raises $16M
Intradigm, a Palo Alto biotech company that is using a technology called “RNA interference” (RNAi) to target genes while providing oncology medical treatments, has raised $16 million in a first round of funding.
It has also moved to Palo Alto, from Rockville, Maryland, driven by the need for better research and development talent, it said.
The round, which occurred in May 2006 was co-led by Alta
Partners and Frazier Healthcare Ventures. Existing investors Emerging Technology Partners (ETP) and… Continue Reading